To Read the Recap, Click Here.
PODD convened 1,000 senior drug delivery executives from pharmaceutical, biotech, medical device, and across all areas of drug delivery focused on developing more effective therapies for patients, improving the patient experience of taking medicine and extending the life cycle of the medicine through collaboration and innovation.
The 2025 keynotes brought insights and inspiration for the PODD audience.
Day One began with the Opening Keynote where Dr Lotte Bjerre Knudsen, Chief Scientific Advisor, Novo Nordisk, presented on clinical data from GLP-1 Receptor Agonists, mechanism of action learnings, new insights and where drug delivery can improve their efficacy. For the Annual Keynote Fireside Discussion, Dr Robert Langer was joined by Dr Lotte Bjerre Knudsen about going beyond single digit oral bioavailability for peptides, brain delivery, how they think about IP and being scientifically courageous. Roche’s Dr Beate Bittner spoke about market trends, drug approval highlights, drug delivery partnerships and highlighted therapeutic areas in her Industry Overview on the 2025 Drug Delivery Landscape.
Day Two began with Patient Keynote, Jimi Olaghere, who spoke about how a CRISPR-based therapy changed his life with sickle cell disease and how the industry can better enable wider access to these life-changing medicines. Zeitgeist presenter, Dr Mansoor Amiji, PhD, University Distinguished Professor, Northeastern University discussed Endogenous Targeted Delivery Strategies to Advance Nucleic Acid Therapeutics.
Across the two days, there were panel discussions on:
- Partnering to Advance Drug Delivery Innovation
- Payer Perspectives on Drug Delivery
- Beyond LNPs: Delivering Genetic Medicines with Novel Vehicles
- Physical and Formulation Approaches for Brain Delivery
- Expanding Transdermal Delivery Opportunities
- Establishing a Regulatory Framework for Global Combination Device Development
- Advances and Opportunities in Dual Chamber Injectables
- Advances in Payload Delivery and Drug Conjugation and Bioconjugation
- Enabling At-Home Delivery of Vaccines
- Achieving Effective Manufacturing Scaleup for Clinical and Commercial Success
- Using Digital Technologies to Enhance Patient Experience and Better Manage Supply Chain
- Platform Approaches to Streamline Combination Product Development
- The Shift from IV to SC Delivery: Patient and Provider Perspectives
- Novel Approaches to Achieve Tissue-Specific Targeting for Nucleic Acid Therapeutics
- Drug Delivery in the Golden Age of Peptides and Biologics: Novel Approaches for Oral Delivery
- New Progress in Ophthalmic Delivery
- Ensuring Sustainability Throughout Drug anDevice Development
- Challenges and Opportunities in Delivering Hyperconcentrated Formulations
- Accomplishing Sustained Release and Long Acting Delivery
- Respiratory Devices and Inhaled Biologics
- Utilizing AI to Facilitate Combination Product Development
- Novel Approaches to Deliver Large Volume Therapies
Across multiple tracks, PODD speakers presented case studies and thought-provoking presentations on:
- Injectable Formulations & Technologies
- Cell, Gene & Novel Biologics Delivery
- Novel Devices: Self-Injectables, Wearables & Connected Devices
- Novel Non-Injectable Technologies
- Novel Materials & Excipient Innovation
- Novel Device Technologies
- Novel Injectable and Non-Injectable Technologies
- Self-Injection Devices, Syringes, Primary Container & Packaging Solutions
We hope you enjoy this recap of the 15th annual PODD. the 16th annual PODD will be back in Boston October 29-30, 2026.
